The p53-Driven Anticancer Effect of Ribes fasciculatum Extract on AGS Gastric Cancer Cells

Abstract

Cancer metastasis is directly related to the survival rate of cancer patients. Although cancer metastasis proceeds by the movement of cancer cells, it is fundamentally caused by its resistance to anoikis, a mechanism of apoptosis caused by the loss of adhesion of cancer cells. Therefore, it was found that inhibiting cancer migration and reducing anoikis resistance are important for cancer suppression, and natural compounds can effectively control it. Among them, Ribes fasciculatum, which has been used as a medicinal plant, was confirmed to have anticancer potential, and experiments were conducted to prove various anticancer effects by extracting Ribes fasciculatum (RFE). Through various experiments, it was observed that RFE induces apoptosis of AGS gastric cancer cells, arrests the cell cycle, induces oxidative stress, and reduces mobility. It was also demonstrated that anoikis resistance was attenuated through the downregulation of proteins, such as epidermal growth factor receptor (EGFR). Moreover, the anticancer effect of RFE depends upon the increase in p53 expression, suggesting that RFE is suitable for the development of p53-targeted anticancer materials. Moreover, through xenotransplantation, it was found that the anticancer effect of RFE confirmed in vitro was continued in vivo.

Construction of an original anoikis-related prognostic model closely related to immune infiltration in gastric cancer

“…Numbers of molecules and pathways have been confirmed to be involved in the anoikis resistance, which resulted in the metastasis and progression of GC ( Li et al, 2020b ; Ye et al, 2020 ; Zhang et al, 2022a ; Li et al, 2022b ). In addition, by reducing anoikis resistance and cancer cell mobility, some drugs could trigger apoptosis and inhibit metastasis, thereby delaying the progression of GC ( Kim et al, 2022 ). All of the above emphasized that the notion of targeting genes associated with anoikis might be imperative to control tumor development and progression.…”